Intratumoral IL-12 Gene Therapy Results in the Crosspriming of Tc1 Cells Reactive Against Tumor-associated Stromal Antigens
Authors: Xi Zhao, Anamika Bose, Hideo Komita, Jennifer L Taylor, Mayumi Kawabe, Nina Chi, Laima Spokas, Devin B Lowe, Christina Goldbach, Sean Alber, Simon C Watkins, Lisa H Butterfield, Pawel Kalinski, John M Kirkwood, Walter J Storkus
Journal: Molecular Therapy (2010)

HLA-A2 transgenic mice bearing established HLA-A2neg B16 melanomas were effectively treated by intratumoral (i.t.) injection of syngeneic dendritic cells (DCs) transduced to express high levels of interleukin (IL)-12, resulting in CD8+ T cell-dependent antitumor protection. In this model, HLA-A2-restricted CD8+ T cells do not directly recognize tumor cells and therapeutic benefit was associated with the crosspriming of HLA-A2-restricted type-1 CD8+ T cells reactive against antigens expressed by stromal cells [i.e., pericytes and vascular endothelial cells (VEC)]. IL-12 gene therapy-induced CD8+ T cells directly recognized HLA-A2+ pericytes and VEC flow-sorted from B16 tumor lesions based on interferon (IFN)-γ secretion and translocation of the lytic granule-associated molecule CD107 to the T cell surface after coculture with these target cells. In contrast, these CD8+ T effector cells failed to recognize pericytes/VEC isolated from the kidneys of tumor-bearing HHD mice. The tumor-associated stromal antigen (TASA)-derived peptides studied are evolutionarily conserved and could be recognized by CD8+ T cells harvested from the blood of HLA-A2+ normal donors or melanoma patients after in vitro stimulation. These TASA and their derivative peptides may prove useful in vaccine formulations against solid cancers, as well as, in the immune monitoring of HLA-A2+ cancer patients receiving therapeutic interventions, such as IL-12 gene therapy. HLA-A2 transgenic mice bearing established HLA-A2neg B16 melanomas were effectively treated by intratumoral (i.t.) injection of syngeneic dendritic cells (DCs) transduced to express high levels of interleukin (IL)-12, resulting in CD8+ T cell-dependent antitumor protection. In this model, HLA-A2-restricted CD8+ T cells do not directly recognize tumor cells and therapeutic benefit was associated with the crosspriming of HLA-A2-restricted type-1 CD8+ T cells reactive against antigens expressed by stromal cells [i.e., pericytes and vascular endothelial cells (VEC)]. IL-12 gene therapy-induced CD8+ T cells directly recognized HLA-A2+ pericytes and VEC flow-sorted from B16 tumor lesions based on interferon (IFN)-γ secretion and translocation of the lytic granule-associated molecule CD107 to the T cell surface after coculture with these target cells. In contrast, these CD8+ T effector cells failed to recognize pericytes/VEC isolated from the kidneys of tumor-bearing HHD mice. The tumor-associated stromal antigen (TASA)-derived peptides studied are evolutionarily conserved and could be recognized by CD8+ T cells harvested from the blood of HLA-A2+ normal donors or melanoma patients after in vitro stimulation. These TASA and their derivative peptides may prove useful in vaccine formulations against solid cancers, as well as, in the immune monitoring of HLA-A2+ cancer patients receiving therapeutic interventions, such as IL-12 gene therapy.